Sienna Biopharmaceuticals Inc. launched less than two years ago, but with a clinical pipeline of dermatology and aesthetics drugs developed by a team experienced in these two markets, the company has been able to raise $160.75m since early 2016 – including a recent $74.75m initial public offering.
Sienna CEO: IPO Investors Drawn By Experienced Dermatology Team
Sienna Biopharmaceuticals went from Series A to IPO in 15 months, selling investors on its executive team experienced in the development and commercialization of dermatology and aesthetic products.
More from Financing
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Public Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
More from Business
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.